In recent years, the United States has witnessed a significant surge in the use of GLP-1 (glucagon-like peptide-1) medications, a class of drugs primarily prescribed for weight loss and the management of type 2 diabetes. According to a Gallup poll released on July 7, 2026, 11% of U.S. adults reported currently using GLP-1 medications for weight loss, a substantial increase from 3% in 2024. Common side effects include fatigue (16.7%), vomiting (16.3%), constipation (15.3%), and diarrhea (12.6%). Additionally, reproductive symptoms and temperature-related complaints have emerged as unrecognized potential effects. These findings underscore the need for comprehensive monitoring and reporting of adverse effects associated with GLP-1 drug use.
Impact on Healthcare Systems
The increasing prevalence of GLP-1 usage has significant implications for healthcare systems. The RAND Corporation's survey from August 2025 revealed that nearly 12% of Americans have used GLP-1 drugs for weight loss, with usage rates highest among women aged 50 to 64. This demographic shift necessitates adjustments in healthcare delivery, including the need for healthcare providers to stay informed about the latest treatments and potential side effects.
Conclusion
The rise in GLP-1 drug usage in the United States reflects a growing interest in pharmacological solutions for weight management and metabolic health. While these medications offer promising benefits, they also present challenges related to cost, accessibility, and potential side effects. Addressing these issues requires a multifaceted approach, including policy interventions to improve affordability, enhanced patient education on potential risks, and ongoing research to monitor long-term health outcomes associated with GLP-1 drug use.